Abstract: Provided herein are compounds, thioester prodrugs thereof, compositions, and methods for the treatment of diseases and disorders associated with renal anomalies.

Abstract: The present disclosure provides certain processes of making 3-fluoro-5-(((1S,2aR)-1,3,3,4,4-pentafluoro-2a-hydroxy-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-7-yl)oxy)-benzonitrile (Compound 1) and certain polymorphs thereof. Also provided are pharmaceutical compositions comprising a crystalline polymorph form of Compound 1 and processes for preparing such polymorph forms.

Abstract: Provided herein are novel compounds, pharmaceutical compositions containing such compounds and methods for their use. In particular, the compounds described herein are useful for the treatment or prevention of diseases associated with T cell proliferation such as autoimmune diseases and disorders.

Abstract: Provided herein are Compounds having the following structure: wherein A, L, X and ring B are as defined herein, compositions comprising an effective amount of a Compound and methods for treating or preventing cancer, hypoxia, diabetes, stroke, autoimmune disease or a condition treatable or preventable by inhibition of Chk2, the ATM-Chk2 pathway or RSK2 comprising administering an effective amount of a Compound to a patient in need thereof.

Abstract: The present invention provides angiogenesis inhibitor compounds comprising a MetAP-2 inhibitory core coupled to a peptide, as well as pharmaceutical compositions comprising the angiogenesis inhibitor compounds and a pharmaceutically acceptable carrier. The present invention also provides methods of treating an angiogenic disease, e.g., cancer, in a subject by administering to the subject a therapeutically effective amount of one or more of the angiogenesis inhibitor compounds of the invention.

Abstract: The present invention provides methods of treating a lymphoma (e.g.

Abstract: The present invention provides angiogenesis inhibitor compounds comprising a MetAP-2 inhibitory core coupled to a peptide, as well as pharmaceutical compositions comprising the angiogenesis inhibitor compounds and a pharmaceutically acceptable carrier. The present invention also provides methods of treating an angiogenic disease, e.g., cancer, in a subject by administering to the subject a therapeutically effective amount of one or more of the angiogenesis inhibitor compounds of the invention.

Abstract: The present invention provides methods of treating an autoimmune disorder (e.g., lupus erythematosus, multiple sclerosis, myasthenia gravis, vasculitis and diabetes mellitus) in a subject by administering to the subject a therapeutically effective amount of one or more compounds of the invention.

Abstract: Disclosed is a method of halogenating the ring of an aromatic compound. The aromatic compound is contacted with a halogenating agent in the presence of a heterogeneous catalyst. The catalyst is the calcination reaction product of: (A) 51 to 99 wt % of a support which comprises at least one inorganic oxide or hydroxide of at least one metal that is at least divalent and forms a metal-to-oxygen matrix during calcination; and (B) 1 to 49 wt % of at least one dopant which comprises a compound that places an element that is at least divalent, bonded to oxygen atoms, into said matrix during said calcination, resulting in the formation of an acidic solid.

Abstract: Disclosed is a method of making a mercaptan by reacting hydrogen sulfide with an olefin in the presence of a heterogeneous acidic catalyst. The catalyst can be made by calcining a mixture of a hydroxide, such as Zr(OH).sub.4 or Ti(OH).sub.4, with an acidic site donor, such as H.sub.2 SO.sub.4, (NH.sub.4).sub.2 SO.sub.4, or WO.sub.3.

Abstract: Disclosed is a method of halogenating the ring of an aromatic compound. The aromatic compound is contacted with a halogenating agent in the presence of a heterogeneous catalyst. The catalyst is the calcination reaction product of:(A) 51 to 99 wt % of a support which comprises at least one inorganic oxide or hydroxide of at least one metal that is at least divalent and forms a metal-to-oxygen matrix during calcination; and(B) 1 to 49 wt % of at least one dopant which comprises a compound that places an element that is at least divalent, bonded to oxygen atoms, into said matrix during said calcination, resulting in the formation of an acidic solid.

Abstract: Disclosed is a method of making a mercaptan by reacting an aliphatic alcohol with hydrogen sulfide in a continuous gaseous phase reaction. The reaction is performed in the presence of a catalyst which comprises a catalytically active carrier that contains base and/or acid active sites, an alkali metal or alkaline earth metal bicarbonate, carbonate, oxide, or hydroxide, and a transition metal acid or alkali metal or alkaline earth metal salt thereof. Selectivities of close to 100% are obtained.